What is it about?
This review summarizes the alterations of classical neurotransmitters and neuropeptides in the extrapyramidal system in Parkinson's disease. The authors suggest a multimodal pharmacotherapy.
Featured Image
Why is it important?
It is important to combine dopaminergic drugs with NMDA antagonists and 5-HT2A antagonists or with m5Glu antagonists and A2A adenosin receptor antagonists.
Perspectives
Clinical trials should be carried out in order to find out whether a multimodal pharmacotherapy is superior to dopaminergic therapy
Dr Felix-Martin Werner
Euro Akademie Pößneck
Read the Original
This page is a summary of: Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs, Current Drug Therapy, December 2015, Bentham Science Publishers,
DOI: 10.2174/157488551002151222154335.
You can read the full text:
Contributors
The following have contributed to this page
